BiotechTube

Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Graft-versus-host Disease (GVHD)

Conditions

Graft-versus-host Disease (GVHD)

Trial Timeline

Jun 29, 2017 → Dec 15, 2022

NCT ID
NCT03112603

About Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib

Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib is a phase 3 stage product being developed by Incyte for Graft-versus-host Disease (GVHD). The current trial status is completed. This product is registered under clinical trial identifier NCT03112603. Target conditions include Graft-versus-host Disease (GVHD).

What happened to similar drugs?

0 of 5 similar drugs in Graft-versus-host Disease (GVHD) were approved

Approved (0) Terminated (0) Active (5)
🔄Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
🔄INCA034176 + Best Available Therapy (BAT)IncytePhase 3
🔄INCA034176IncytePhase 3
🔄Itacitinib + Placebo + Prednisone + MethylprednisoloneIncytePhase 3
🔄INCA034176 + Placebo + CorticosteroidsIncytePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03112603Phase 3Completed

Competing Products

20 competing products in Graft-versus-host Disease (GVHD)

See all competitors
ProductCompanyStageHype Score
AlefaceptAstellas PharmaPhase 2
27
EQ001 + EQ001 PlaceboBioconPhase 1/2
32
SHR0302Jiangsu Hengrui MedicinePhase 1
29
Prednisone + Jakavi(ruxolitinib) + PrednisoneNovartisPhase 2
42
PredEverNovartisPhase 2
35
Lifitegrast 5% Ophthalmic Solution + PlaceboNovartisPhase 1
29
LBH589 + MethylprednisoloneNovartisPhase 2
27
Panobinostat (LBH589)NovartisPhase 1/2
32
FilgrastimAmgenPre-clinical
18
AMG 592AmgenPhase 1
29
AMG 592AmgenPhase 1
29
BMS-986004 + Sirolimus + TacrolimusBristol Myers SquibbPhase 1
29
Belumosudil (KD025)SanofiPhase 2
27
Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QDSanofiPhase 2
35
AAT + PlaceboCSLPhase 2/3
42
Ruxolitinib + MethylprednisoloneIncytePhase 2
39
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)IncytePhase 3
44
Itacitinib + CorticosteroidsIncytePhase 1/2
21
RuxolitinibIncytePre-clinical
23
Itacitinib + CorticosteroidIncytePhase 1
26